Pliant Therapeutics closed at $0.85 on Nov 4, down 1.03%, within 1.5% of its 52-week closing low. Volume of 205.3K shares was 0.54× its 20-day average (below normal).
Split-adjusted performance: -17.3% over one month, -30.7% over six months, -49.0% over one year.
Short interest was 4.6M shares at the Oct 15 settlement, up 9.1% from the prior report (9.6% of float, 10.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | |
| HOWLWerewolf Therapeutics | $1.09 | +1.87% | +67.6% | — | 17.5% | — | $53.0M | Compare |
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | Compare |
| ANVSAnnovis Bio | $1.21 | +11.01% | −49.6% | — | — | — | $51.6M | Compare |
| IBIOiBio | $0.8000 | −2.85% | −54.8% | −100.0% | — | — | $51.4M | Compare |
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | Compare |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
